Dr. Ana Aparicio of the University of Texas MD Anderson Cancer Center discusses exciting scientific and clinical research for prostate cancer treatment, as well as biomarkers and genomic sequencing, combination therapies, clinical trials, and side effects. #pcsm #CRIsummit #immunotherapy [ Ссылка ]
00:00- Tamron Hall introduces Dr. Ana Aparicio
00:57 - Dr. Aparicio discusses prostate cancer and immunotherapy
06:20- Brian Brewer leads a Q&A from the audience with Dr. Aparicio
As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. [ Ссылка ]
Questions from the audience for Dr. Aparicio:
- I'm currently undergoing immunotherapy (durvalumab). Is it okay to get the COVID-19 vaccine?
- In your opinion, what is the most promising way to make a cold tumor hot?
- Is immunotherapy effective on prostate cancer that has metastasized? At what stage should one even consider immunotherapy?
- Are immunotherapies typically used on those with more advanced states of metastatic prostate cancer or can they be used in the early stages of detection?
- Is genomic sequencing valuable? Do you recommend this to all of your patients?
Ana Aparicio is an associate professor at MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology, who specializes in the treatment of advanced prostate cancer. Her clinical and translational research focuses on the development of novel therapies for a subset of aggressive prostate cancer.
The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. [ Ссылка ]
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. [ Ссылка ]
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
